Irodalom:
1. ALLAL AS, ZWAHLEN D, BRUNDLER MA.ET AL: Neoadjuvant radiochemotherapy for locally advanced
gastric cancer: long-term results of a phase I trial. Int J Radiat Oncol Biol Phys. 2005 Dec
1;63(5):1286-9.
2. ALTINBAS M, ER O, OZKAN M. ET AL: Irinotecan plus cisplatin combination against metastatic
gastric cancer: phase II study. Med Oncol. 2005;22(2):153-60.
3. AOYAGI K, KOUHUJI K, YANO S. ET AL: VEGF signifi cance in peritoneal recurrence from gastric
cancer. Gastric Cancer. 2005;8(3):155-63.
4. ASHIZAWA T, OKADA R, SUZUKI Y. ET AL: Clinical signifi cance of interleukin-6 (IL-6) in the spread of
gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer. 2005;8(2):124-31.
5. BACANI J, ZWINGERMAN R, DI NICOLA N.ET AL: Tumor microsatellite instability in early onset gastric
cancer. J Mol Diagn. 2005 Oct;7(4):465-77.
6. CHANG HM, KIM TW, RYU BY. ET AL: Phase II study of paclitaxel and carboplatin in advanced gastric
cancer previously treated with 5-fl uorouracil and platinum. Jpn J Clin Oncol. 2005 May;35(5):251-5.
7. CHEN JS, HUANG JS, YANG TS. ET AL: Phase I dose escalation study of oxaliplatin combined with
oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. Anticancer Drugs.
2005 Jan;16(1):47-51.
8. CHO EK, LEE WK, IM SA. ET AL: A phase II study of epirubicin, cisplatin and capecitabine
combination chemotherapy in patients with metastatic or advanced gastric cancer. Oncology.
2005;68(4-6):333-40.
9. CHUN JH, KIM HK, LEE JS. ET AL: Weekly docetaxel in combination with capecitabine in patients
with metastatic gastric cancer. Am J Clin Oncol. 2005 Apr;28(2):188-94.
10. COPIE-BERGMAN C, LOCHER C, LEVY M. ET AL: Metachronous gastric MALT lymphoma and early
gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?
Ann Oncol. 2005 Aug;16(8):1232-6.
11. CORREALE P, FULFARO F, MARSILI S. ET AL: Gemcitabine (GEM) plus oxaliplatin, folinic acid, and
5-fl uorouracil (FOLFOX-4) in patients with advanced gastric cancer. Cancer Chemother
Pharmacol. 2005 Dec;56(6):563-8.
12. DE VITA F, ORDITURA M, MATANO E. ET AL: A phase II study of biweekly oxaliplatin plus infusional
5-fl uorouracil and folinic acid (FOLFOX-4) as fi rst-line treatment of advanced gastric cancer
patients. Br J Cancer. 2005 May 9;92(9):1644-9.
13. DOEKHIE FS, MESKER WE, VAN KRIEKEN JH. ET AL: Clinical relevance of occult tumor cells in lymph
nodes from gastric cancer patients. Am J Surg Pathol. 2005 Sep;29(9):1135-44.
14. FELICI A, CARLINI P, RUGGERI EM .ET AL: Bi-weekly chemotherapy with cisplatin, epirubicin, folinic
acid and 5-fl uorouracil continuous infusion plus g-csf in advanced gastric cancer: a multicentric
phase II study. Cancer Chemother Pharmacol. 2006 Jan;57(1):59-64.
15. FUJITANI K, NARAHARA H, TAKIUCHI H.ET AL: Phase I and pharmacokinetic study of S-1 combined
with weekly paclitaxel in patients with advanced gastric cancer. Oncology. 2005;69(5):
414-20.
16. GIULIANI F, MOLICA S, MAIELLO E.ET AL: Irinotecan (CPT-11) and mitomycin-C (MMC) as secondline
therapy in advanced gastric cancer a phase II study of the Gruppo Oncologico dell’ Italia
Meridionale (prot.2106). Am J Clin Oncol. 2005 Dec;28(6):581-5.
17. GNAD-VOGT SU, HOFHEINZ RD, SAUSSELE S. ET AL: Pegylated liposomal doxorubicin and mitomycin
C in combination with infusional 5-fl uorouracil and sodium folinic acid in the treatment of
advanced gastric cancer: results of a phase II trial. Anticancer Drugs. 2005 Apr;16(4):
435-40.
18. GOTO Y, ANDO T, GOTO H.ET AL: No association between EGF gene polymorphism and gastric
cancer. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2454-6.
19. HAMADA M, TSUJI A, TWATA J. ET AL: Neoadjuvant chemotherapy with S-1 and surgical resection
for a mucinous gastric cancer with peritoneal dissemination. Gastric Cancer. 2005;8(1):
50-4.
20. IKEGUCHI M, MATSUMOTO S, YOSHIOKA S. ET AL: Laparoscopic-assisted intraperitoneal chemotherapy
for patients with scirrhous gastric cancer. Chemotherapy. 2005 Mar;51(1):15-20.
21. ISHIZAWA T, YAMAMOTO T, NISHIDA K .ET AL: Diagnostic value of measuring liver volume for detecting
occult hepatic metastases from colorectal or gastric cancer. World J Surg. 2005 Jun; 29(6):719-22.
A gyomor | 119
120 | Gastro Update 2006
22. IWAHASHI M, NAKAMORI M, NAKAMURA M. ET AL: Individualized adjuvant chemotherapy guided by
chemosensitivity test sequential to extended surgery for advanced gastric cancer. Anticancer
Res. 2005 Sep-Oct;25(5):3453-9.
23. IWASE H, SHIMADA M, TSUZUKI T. ET AL: A phase II multicentric trial of S-1 combined with 24 hinfusion
of cisplatin in patients with advanced gastric cancer. Anticancer Res. 2005 MarApr;25(2B):1297-301.
24. KANG HJ, CHANG HM, KIM TW. ET AL: Phase II study of capecitabine and cisplatin as fi rst-line
combination therapy in patients with gastric cancer recurrent after fl uoropyrimidine-based
adjuvant chemotherapy. Br J Cancer. 2005 Jan 31;92(2):246-51.
25. KAWAKAMI K, GRAZIANO F, WATANABE G. ET AL: Prognostic role of thymidylate synthase polymorphisms
in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res.
2005 May 15;11(10):37778-83.
26. KIM JG, SOHN SK, KIM DH. ET AL: Phase II study of docetaxel and capecitabine in patients with
metastatic or recurrent gastric cancer. Oncology. 2005;68(2-3):190-5.
27. KIM ST, KANG WK, KANG JH. ET AL: Salvage chemotherapy with irinotecan, 5-fl uorouracil and
leucovorin for taxane-and cisplatin-refractory, metastatic gastric cancer. Br J Cancer. 2005
May 23;92(10):1850-4.
28. KOIZUMI W, KURIHARA M, SATOH A. ET AL: Phase 1/11 study of bi-weekly irinotecan plus cisplatin in
the treatment of advanced gastric cancer. Anticancer Res. 2005 Mar-Apr;25(2B):1257-62.
29. KOLLMANNSBERGER C, BUDACH W, STAHL M. ET AL: Adjuvant chemoradiation using 5-fl uorouracil/
folinic acid/cisplatin with or withouth paclitaxel and radiation in patients with completely
resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann
Oncol. 2005 Aug; 16(8):1326-33.
30. KONDO K, KOBAYASHI M, KOJIMA H. ET AL: Phase I evaluation of continuous 5-fl uorouracil infusion
followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer. Jpn J Clin
Oncol. 2005 Jun;35(6):332-7.
31. KUNISAKI C, SHIMADA H, NOMURA M. ET AL: Therapeutic strategy for scirrhous type gastric cancer.
Hepatogastroenterology. 2005 Jan-Feb;52(61):310-3.
32. LEE JH, KIM J, CHEONG JH. ET AL: Gastric cancer surgery in cirrhotic patients: result of gastrectomy
with D2 lymph node dissection. World J Gastroenterol. 2005 Aug 14;11(30):4623-7.
33. LIU P, ZHANG XY, SHAO Y. ET AL: Microsatellite instability in gastric cancer and pre-cancerous
lesions. World J Gastroenterol. 2005 Aug 21;11(31):4904-7.
34. LORDICK F, LORENZEN S, STOLLFUSS J.ET AL: Phase II study of weekly oxaliplatin plus infusional
fl uorouracil and folnic acid (FUFOX regimen) as fi rst-line treatment in metastatic gastric cancer.
Br J Cancer. 2005 Jul 25;93(2):190-4.
35. MARIANI L, MICELI R, LUSA L.ET AL: A modifi ed prognostic score for patients with curatively resected
gastric cancer. Tumor. 2005 May-Jun;91(2):221-6.
36. MOEHLER M, EIMERMACHER A, SIEBLER J. ET AL: Randomised phase II evaluation of irinotecan plus
high-dose 5-fl uorouracil and leucovorin (ILF) vs 5-fl uorouracil, leucovorin, and etoposide (ELF)
in untreated metastatic gastric cancer. Br J Cancer. 2005 Jun 20;92(12):2122-8.
37. Moiseyenko VM, Ajani SA, Tjulandin A et al: Final results of a randomized controlled phase
III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fl uorouracil (F)
to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). American Society of
Clinical Oncology Meeting Proceedings, Volume 24, 2005.
38. MORIWAKI T, HYODO I, NISHINA T. ET AL: A phase I study of doxifl uridine combined with weekly paclitaxel
for metastatic gastric cancer. Cancer Chemother Pharmacol. 2005 Aug;56(2):138-44.
39. NITTI D, MARCHET A, MAMMANO E. ET AL: Extended lymphadenectomy (D2) in patients with early
gastric cancer. Eur J Surg Oncol. 2005 Oct;31(8):875-81.
40. OH DY, KIM TY, KWON JH. ET AL: Docetaxel + 5-fl uorouracil + cisplatin 3-day combination
chemotherapy as a fi rst-line treatment in patients with unresectable gastric cancer. Jpn J Clin
Oncol. 2005 Jul;35(7):380-5.
41. OH SC, PARK KH, CHOI IK. ET AL: Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination
chemotherapy in advanced gastric cancer. Br J Cancer. 2005 Mar 14;92(5):827-31.
42. OTSUJI E, FUJIYAMA J, TAKAGI T. ET AL: Results of total gastrectomy with extended lymphadenectomy
for gastric cancer in elderly patients. J Surg Oncol. 2005 Sep 15;91(4):232-6.
43. PARK SH, LEE J, LEE SH. ET AL: Anaemia is the strongest prognostic factor for outcomes of 5-
fl uorouracil-based fi rst-line chemotherapy in patients with advanced gastric cancer. Cancer
Chemother Pharmacol. 2006 Jan;57(1):91-6.
44. PERSIANI R, D’UGO D, RAUSEI S. ET AL: Prognostic indicators in locally advanced gastric cancer
(LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol. 2005 Mar
15;89(4):227-36. discussion 237-8.
45. PETRIOLI R, SABATINO M, ROVIELLO F.ET AL: Folinic acid, 5-fl uorouracil and etoposide after curative
resection for gastric cancer. Hepatogastroenterology. 2005 Sep-Oct;52(65):1626-30.
46. PUTTER H, SASAKO M, HARTGRINK HH. ET AL: Long-term survival with non-proportional hazards:
results from the Dutch Gastric Cancer Trial. Stat Med. 2005 Sep 30;24(18):2807-21.
47. RINGASH J, KHAKSART SJ, OZA A ET AL: Post-operative radiochemotherapy for gastric cancer:
adoption and adaptation. Clin Oncol (R Coll Radiol). 2005 Apr;17(2):91-5.
48. RINGASH J, PERKINS G, BRIERLEY J. ET AL: IMRT for adjuvant radiation in gastric cancer: a preferred
plan? Int J Radiat Oncol Phys. 2005 Nov 1;63(3):732-8.
49. RUDI J, WERLE S, BERGTHOLDT D. ET AL: Infusional 5-fl uorouracil and mitomycin C: an effective
regimen in the treatment of advanced gastric cancer. Onkologie. 2005 Mar;28(3): 128-32.
50. SAIKAWA Y, KUBOTA T, TAKAHASHI T. ET AL: Is chemoradiation effective of harmful for stage IV gastric
cancer patients? Oncol Rep. 2005 May;13(5):865-70.
51. SAKAGUCHI Y, KABASHIMA A, OKITA K. ET AL: Long-term outcome of S-1 and cisplatin combination
therapy in patients with advanced or recurrent gastric cancer. Gastric Cancer. 2005;8(2):
111-6.
52. SATO Y, KONDO H, HONDA K. ET AL: A phase I/II study of S-1 plus cisplatin in patients with advanced
gastric cancer: 2-week S-1 administration regimen. Int J Clin Oncol. 2005 Feb;10(1):40-4.
53. SHEN JG, CHEONG JH, HYUNG WJ. ET AL: Pretreatment anaemia is associated with poorer survival
in patients with stage I and II gastric cancer. J Surg Oncol. 2005 Aug 1;91(2):126-30.
54. SHIN SJ, CHUN SH, KIM KO.ET AL: The effi cacy of paclitaxel and cisplatin combination chemotherapy
for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. Korean
J Intern Med. 2005 Jun;20(2):135-40.
55. STAHL M, MULLER C, KOSTER W.ET AL: Second-line chemotherapy of advanced disseminated
gastric cancer after cisplatin, infusional 5-fl uorouracil, folinic acid (PLF):benefi t dependent on
progression-free interval after fi rst-line therapy. Onkologie. 2005 Oct;28(10):499-502.
56. TAKAHASHI N, KASHIWAGI H, IWABUCHI S. ET AL: Phase I study of a weekly schedule of fi xed-dose
paclitaxel and escalating doses of cisplatin for recurrent or unresectable gastric cancer in
Japan. Am J Clin Oncol. 2005 Jun;28(3):242-7.
57. TAKAHASHI N, SUZUKI H, TWABUCHI S. ET AL: Third-line chemotherapy with paclitaxel, irinotecan
hydrochloride and cisplatin for recurrent gastric cancer a case report. Hepatogastroenterology.
2005 Jan-Feb;52(61):326-8.
58. TAKEYOSHI I, IWANAMI K, YAMADA T. ET AL: Advanced gastric cancer with peritoneal dissemination
successfully treated with paclitaxel and doxifl uridine: a case report. Hepatogastroenterology.
2005 Jan-Feb;52(61):322-5.
59. TAKEYOSHI I, MAKITA F, TANAHASHI Y. ET AL: A combination phase I study of weekly paclitaxel and
doxifl uridine in advanced gastric cancer patients. Anticancer Res. 2005 Mar-Apr;25(2B):1291-6.
60. TAKIUCHI H, NARAHARA H, TSUJINAKA T.ET AL: Phase I study of S-1 combined with irinotecan (CPT-11) in
patients with advanced gastric cancer (OGSG 0002) Jpn J Clin Oncol. 2005 Sep;35(9):520-5.
61. TROJAN J, KIM SZ, ENGELS K. ET AL: In vitro chemosensitivity to gemcitabine, oxaliplatin and
zoledronic acid predicts treatment response in metastatic gastric cancer. Anticancer Drugs,
2005 Jan;16(1):87-91.
A gyomor | 121
122 | Gastro Update 2006
62. UEDA Y, YAMAGISHI H, ICHIKAWA D. ET AL: Phase I study of a combination of s-1 and weekly paclitaxel
in patients with advanced or recurrent gastric cancer. Oncology. 2005;69(3):261-8.
63. YEH KH, LU YS, HSU CH. ET AL: Phase II study of weekly paclitaxel and 24-hour infusion of highdose
5-fl uorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer.
Oncology.2005;69(1):88-95.
64. YONEMURA Y, KAWAMURA T, BANDOU E. ET AL: Treatment of peritoneal dissemination from gastric
cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005
Mar;92(3):370-5.
